Aurobindo Pharma Q3 Net Profit Rises 8% to Rs 910 Cr

Written By :  sheeba farhat
Published On 2026-02-10 10:30 GMT   |   Update On 2026-02-10 14:08 GMT
Advertisement

New Delhi: Aurobindo Pharma on Monday said its consolidated net profit increased 8 per cent year-on-year to Rs 910 crore for the December quarter, led by robust sales in Europe and the US.

The Hyderabad-based drug major reported a net profit of Rs 846 crore for the October-December period of the last fiscal year. Total revenue from operations increased to Rs 8,646 crore during the quarter as compared with Rs 7,979 crore in the year-ago period, the drug firm said in a statement.

Advertisement

"Q3 reflected steady execution across Aurobindo's core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the US and Europe," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said.

Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability, he added.

"As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation over the medium term," Reddy said.

Also Read: Aurobindo Arm CuraTeQ Gets Health Canada NOC for Pegfilgrastim Biosimilar Dyrupe

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News